Latest Sales Growth News

Metgasco’s latest quarterly report reveals a 24% drop in sales revenue amid ongoing Production Uplift Program activities, while reserves remain stable and strategic farm-out talks advance.

Cobram Estate Olives Limited has reported a record-breaking FY2025, driven by strong sales growth in Australia and the USA, alongside a $178 million equity raise to accelerate its Californian olive grove expansion.

Australian Bond Exchange Holdings (ASX – ABE) unveiled new AUD-denominated market-linked securities and progressed its AI-driven credit analysis tool, while reporting a $0.7 million quarterly cash outflow and plans for capital raising.

Osteopore Limited reported a 7% year-on-year revenue increase in Q3 CY25, secured Swiss market approval for its implants, and saw a threefold sales surge through its Zimmer Biomet partnership.

Novatti Group has achieved positive operating cashflow and EBITDA for the September quarter, driven by strategic revenue reforms and new commercial contracts with major clients.

Bubs Australia reported a 30% increase in net revenue to $25.6 million for Q1 FY26, driven by robust US sales and a return to profitability with positive EBITDA. Despite inventory challenges in other regions, the company maintains a solid cash position and anticipates FDA approval by year-end.

Hydralyte USA reported a 6% year-on-year sales increase in Q3 FY25 alongside a significant 42% reduction in operating cash burn, driven by a streamlined US-focused model and new product launches in brain and gut health.

Endeavour Group’s first quarter results reveal a strong Hotels segment growth of 4.4%, alongside a retail sales recovery that returned to positive territory in September. Online sales surged by 20.9%, highlighting shifting consumer habits.

WA Kaolin Limited has reported a remarkable surge in sales volumes and revenue for the September 2025 quarter, driven by operational upgrades and expanding market reach. The company’s forward orders and product diversification signal robust growth ahead.

Nova Eye Medical reported a robust 32% increase in global sales excluding China for Q1 FY26 and secured regulatory approval for its iTrack™ Advance device in China, setting the stage for expanded market penetration.

Control Bionics reports a strong start to FY26 with nearly 10% revenue growth, expanded US reimbursement coverage, and advancing commercialization of its NeuroNode and NeuroStrip technologies.

Nuchev Limited reported a robust 30% increase in group revenue to $6.5 million in Q1 FY26, driven by strong sales across ANZ, China, and a new foothold in Vietnam. The company’s strategic acquisitions and product launches underpin its expanding market presence and diversification.